Gain Therapeutics, Inc.
Gain Therapeutics, Inc. (GANX) Stock Competitors & Peer Comparison
See (GANX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GANX | $1.50 | -4.46% | 51.9M | -1.81 | -$0.83 | N/A |
| VRTX | $469.16 | +0.16% | 120.5B | -122.23 | -$3.84 | N/A |
| REGN | $554.58 | -0.64% | 58.9B | 14.09 | $39.35 | +0.32% |
| ALNY | $339.80 | +2.80% | 44.3B | -160.28 | -$2.12 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ARGX | $598.89 | +0.02% | 36.7B | 36.50 | $16.41 | N/A |
| BNTX | $110.05 | -1.28% | 26.5B | -29.35 | -$3.75 | N/A |
| RPRX | $37.12 | -0.40% | 20.9B | 15.15 | $2.45 | +2.32% |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| SMMT | $26.66 | -0.30% | 19.8B | -78.41 | -$0.34 | N/A |
Stock Comparison
GANX vs VRTX Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, VRTX has a market cap of 120.5B. Regarding current trading prices, GANX is priced at $1.50, while VRTX trades at $469.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas VRTX's P/E ratio is -122.23. In terms of profitability, GANX's ROE is -2.48%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, GANX is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check VRTX's competition here
GANX vs REGN Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, REGN has a market cap of 58.9B. Regarding current trading prices, GANX is priced at $1.50, while REGN trades at $554.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas REGN's P/E ratio is 14.09. In terms of profitability, GANX's ROE is -2.48%, compared to REGN's ROE of +0.15%. Regarding short-term risk, GANX is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check REGN's competition here
GANX vs ALNY Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, ALNY has a market cap of 44.3B. Regarding current trading prices, GANX is priced at $1.50, while ALNY trades at $339.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas ALNY's P/E ratio is -160.28. In terms of profitability, GANX's ROE is -2.48%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, GANX is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check ALNY's competition here
GANX vs SGEN Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, GANX is priced at $1.50, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas SGEN's P/E ratio is -57.19. In terms of profitability, GANX's ROE is -2.48%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, GANX is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check SGEN's competition here
GANX vs ARGX Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, ARGX has a market cap of 36.7B. Regarding current trading prices, GANX is priced at $1.50, while ARGX trades at $598.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas ARGX's P/E ratio is 36.50. In terms of profitability, GANX's ROE is -2.48%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, GANX is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check ARGX's competition here
GANX vs BNTX Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, BNTX has a market cap of 26.5B. Regarding current trading prices, GANX is priced at $1.50, while BNTX trades at $110.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas BNTX's P/E ratio is -29.35. In terms of profitability, GANX's ROE is -2.48%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, GANX is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check BNTX's competition here
GANX vs RPRX Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, RPRX has a market cap of 20.9B. Regarding current trading prices, GANX is priced at $1.50, while RPRX trades at $37.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas RPRX's P/E ratio is 15.15. In terms of profitability, GANX's ROE is -2.48%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, GANX is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check RPRX's competition here
GANX vs BGNE Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, GANX is priced at $1.50, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas BGNE's P/E ratio is -22.55. In terms of profitability, GANX's ROE is -2.48%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, GANX is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check BGNE's competition here
GANX vs SMMT Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, SMMT has a market cap of 19.8B. Regarding current trading prices, GANX is priced at $1.50, while SMMT trades at $26.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas SMMT's P/E ratio is -78.41. In terms of profitability, GANX's ROE is -2.48%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, GANX is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check SMMT's competition here
GANX vs DNA-WT Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, GANX is priced at $1.50, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, GANX's ROE is -2.48%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, GANX is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check DNA-WT's competition here
GANX vs INCY Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, INCY has a market cap of 15B. Regarding current trading prices, GANX is priced at $1.50, while INCY trades at $77.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas INCY's P/E ratio is 18.33. In terms of profitability, GANX's ROE is -2.48%, compared to INCY's ROE of +0.34%. Regarding short-term risk, GANX is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check INCY's competition here
GANX vs GMAB Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, GMAB has a market cap of 13.8B. Regarding current trading prices, GANX is priced at $1.50, while GMAB trades at $22.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas GMAB's P/E ratio is 13.10. In terms of profitability, GANX's ROE is -2.48%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, GANX is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check GMAB's competition here
GANX vs UTHR Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, UTHR has a market cap of 12.7B. Regarding current trading prices, GANX is priced at $1.50, while UTHR trades at $281.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas UTHR's P/E ratio is 11.23. In terms of profitability, GANX's ROE is -2.48%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, GANX is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check UTHR's competition here
GANX vs KRTX Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, GANX is priced at $1.50, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas KRTX's P/E ratio is -28.09. In terms of profitability, GANX's ROE is -2.48%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, GANX is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check KRTX's competition here
GANX vs MRNA Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, MRNA has a market cap of 12.4B. Regarding current trading prices, GANX is priced at $1.50, while MRNA trades at $32.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas MRNA's P/E ratio is -3.68. In terms of profitability, GANX's ROE is -2.48%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, GANX is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check MRNA's competition here
GANX vs BMRN Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, BMRN has a market cap of 11.3B. Regarding current trading prices, GANX is priced at $1.50, while BMRN trades at $58.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas BMRN's P/E ratio is 21.78. In terms of profitability, GANX's ROE is -2.48%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, GANX is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check BMRN's competition here
GANX vs ASND Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, ASND has a market cap of 10.1B. Regarding current trading prices, GANX is priced at $1.50, while ASND trades at $166.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas ASND's P/E ratio is -24.42. In terms of profitability, GANX's ROE is -2.48%, compared to ASND's ROE of +1.91%. Regarding short-term risk, GANX is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check ASND's competition here
GANX vs EXEL Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, EXEL has a market cap of 9.9B. Regarding current trading prices, GANX is priced at $1.50, while EXEL trades at $36.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas EXEL's P/E ratio is 17.72. In terms of profitability, GANX's ROE is -2.48%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, GANX is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check EXEL's competition here
GANX vs RXDX Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, GANX is priced at $1.50, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas RXDX's P/E ratio is -56.47. In terms of profitability, GANX's ROE is -2.48%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, GANX is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check RXDX's competition here
GANX vs TECH Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, TECH has a market cap of 9B. Regarding current trading prices, GANX is priced at $1.50, while TECH trades at $57.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas TECH's P/E ratio is 69.53. In terms of profitability, GANX's ROE is -2.48%, compared to TECH's ROE of +0.06%. Regarding short-term risk, GANX is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check TECH's competition here
GANX vs VRNA Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, VRNA has a market cap of 8.9B. Regarding current trading prices, GANX is priced at $1.50, while VRNA trades at $105.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas VRNA's P/E ratio is -52.57. In terms of profitability, GANX's ROE is -2.48%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, GANX is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check VRNA's competition here
GANX vs IMGN Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, GANX is priced at $1.50, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas IMGN's P/E ratio is -111.55. In terms of profitability, GANX's ROE is -2.48%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, GANX is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check IMGN's competition here
GANX vs BBIO Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, BBIO has a market cap of 8.7B. Regarding current trading prices, GANX is priced at $1.50, while BBIO trades at $45.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas BBIO's P/E ratio is -12.81. In terms of profitability, GANX's ROE is -2.48%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, GANX is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check BBIO's competition here
GANX vs BPMC Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, GANX is priced at $1.50, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas BPMC's P/E ratio is -51.58. In terms of profitability, GANX's ROE is -2.48%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, GANX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check BPMC's competition here
GANX vs CERE Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, GANX is priced at $1.50, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas CERE's P/E ratio is -16.47. In terms of profitability, GANX's ROE is -2.48%, compared to CERE's ROE of -0.43%. Regarding short-term risk, GANX is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check CERE's competition here
GANX vs ROIVW Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, GANX is priced at $1.50, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, GANX's ROE is -2.48%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, GANX is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check ROIVW's competition here
GANX vs ROIV Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, ROIV has a market cap of 7.7B. Regarding current trading prices, GANX is priced at $1.50, while ROIV trades at $11.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas ROIV's P/E ratio is -15.20. In terms of profitability, GANX's ROE is -2.48%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, GANX is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check ROIV's competition here
GANX vs CORT Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, CORT has a market cap of 7.4B. Regarding current trading prices, GANX is priced at $1.50, while CORT trades at $69.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas CORT's P/E ratio is 60.79. In terms of profitability, GANX's ROE is -2.48%, compared to CORT's ROE of +0.20%. Regarding short-term risk, GANX is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check CORT's competition here
GANX vs HALO Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, HALO has a market cap of 7.4B. Regarding current trading prices, GANX is priced at $1.50, while HALO trades at $60.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas HALO's P/E ratio is 15.98. In terms of profitability, GANX's ROE is -2.48%, compared to HALO's ROE of +1.22%. Regarding short-term risk, GANX is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check HALO's competition here
GANX vs JAZZ Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, JAZZ has a market cap of 7B. Regarding current trading prices, GANX is priced at $1.50, while JAZZ trades at $116.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas JAZZ's P/E ratio is 15.78. In terms of profitability, GANX's ROE is -2.48%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, GANX is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check JAZZ's competition here
GANX vs IONS Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, IONS has a market cap of 6.9B. Regarding current trading prices, GANX is priced at $1.50, while IONS trades at $43.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas IONS's P/E ratio is -14.51. In terms of profitability, GANX's ROE is -2.48%, compared to IONS's ROE of -0.45%. Regarding short-term risk, GANX is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check IONS's competition here
GANX vs RVMD Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, RVMD has a market cap of 6.9B. Regarding current trading prices, GANX is priced at $1.50, while RVMD trades at $37.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas RVMD's P/E ratio is -9.23. In terms of profitability, GANX's ROE is -2.48%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, GANX is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check RVMD's competition here
GANX vs RETA Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, GANX is priced at $1.50, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas RETA's P/E ratio is -66.29. In terms of profitability, GANX's ROE is -2.48%, compared to RETA's ROE of +0.47%. Regarding short-term risk, GANX is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check RETA's competition here
GANX vs MDGL Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, MDGL has a market cap of 6.4B. Regarding current trading prices, GANX is priced at $1.50, while MDGL trades at $289.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas MDGL's P/E ratio is -16.25. In terms of profitability, GANX's ROE is -2.48%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, GANX is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check MDGL's competition here
GANX vs AMRN Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, AMRN has a market cap of 6.2B. Regarding current trading prices, GANX is priced at $1.50, while AMRN trades at $14.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas AMRN's P/E ratio is -3.40. In terms of profitability, GANX's ROE is -2.48%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, GANX is more volatile compared to AMRN. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check AMRN's competition here
GANX vs TGTX Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, TGTX has a market cap of 5.8B. Regarding current trading prices, GANX is priced at $1.50, while TGTX trades at $36.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas TGTX's P/E ratio is 145.08. In terms of profitability, GANX's ROE is -2.48%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, GANX is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check TGTX's competition here
GANX vs NUVL Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, NUVL has a market cap of 5.7B. Regarding current trading prices, GANX is priced at $1.50, while NUVL trades at $79.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas NUVL's P/E ratio is -18.00. In terms of profitability, GANX's ROE is -2.48%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, GANX is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check NUVL's competition here
GANX vs RYTM Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, RYTM has a market cap of 5.6B. Regarding current trading prices, GANX is priced at $1.50, while RYTM trades at $84.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas RYTM's P/E ratio is -30.24. In terms of profitability, GANX's ROE is -2.48%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, GANX is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check RYTM's competition here
GANX vs ABCM Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, GANX is priced at $1.50, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, GANX's ROE is -2.48%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, GANX is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check ABCM's competition here
GANX vs ISEE Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, GANX is priced at $1.50, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas ISEE's P/E ratio is -22.44. In terms of profitability, GANX's ROE is -2.48%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, GANX is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check ISEE's competition here
GANX vs AXSM Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, AXSM has a market cap of 5B. Regarding current trading prices, GANX is priced at $1.50, while AXSM trades at $101.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas AXSM's P/E ratio is -17.55. In terms of profitability, GANX's ROE is -2.48%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, GANX is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check AXSM's competition here
GANX vs CRSP Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, GANX is priced at $1.50, while CRSP trades at $57.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas CRSP's P/E ratio is -12.85. In terms of profitability, GANX's ROE is -2.48%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, GANX is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check CRSP's competition here
GANX vs MRUS Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, MRUS has a market cap of 4.9B. Regarding current trading prices, GANX is priced at $1.50, while MRUS trades at $66.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas MRUS's P/E ratio is -15.90. In terms of profitability, GANX's ROE is -2.48%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, GANX is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check MRUS's competition here
GANX vs ALKS Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, ALKS has a market cap of 4.6B. Regarding current trading prices, GANX is priced at $1.50, while ALKS trades at $27.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas ALKS's P/E ratio is 13.49. In terms of profitability, GANX's ROE is -2.48%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, GANX is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check ALKS's competition here
GANX vs TLX Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, TLX has a market cap of 4.6B. Regarding current trading prices, GANX is priced at $1.50, while TLX trades at $13.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas TLX's P/E ratio is 150.00. In terms of profitability, GANX's ROE is -2.48%, compared to TLX's ROE of +0.06%. Regarding short-term risk, GANX is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check TLX's competition here
GANX vs ABVX Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, ABVX has a market cap of 4.5B. Regarding current trading prices, GANX is priced at $1.50, while ABVX trades at $70.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas ABVX's P/E ratio is -20.41. In terms of profitability, GANX's ROE is -2.48%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, GANX is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check ABVX's competition here
GANX vs PCVX Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, PCVX has a market cap of 4.5B. Regarding current trading prices, GANX is priced at $1.50, while PCVX trades at $34.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas PCVX's P/E ratio is -8.73. In terms of profitability, GANX's ROE is -2.48%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, GANX is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check PCVX's competition here
GANX vs SLNO Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, SLNO has a market cap of 4.5B. Regarding current trading prices, GANX is priced at $1.50, while SLNO trades at $84.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas SLNO's P/E ratio is -17.90. In terms of profitability, GANX's ROE is -2.48%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, GANX is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check SLNO's competition here
GANX vs ALPN Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, GANX is priced at $1.50, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas ALPN's P/E ratio is -101.52. In terms of profitability, GANX's ROE is -2.48%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, GANX is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check ALPN's competition here
GANX vs RNA Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, RNA has a market cap of 4.4B. Regarding current trading prices, GANX is priced at $1.50, while RNA trades at $36.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas RNA's P/E ratio is -12.29. In terms of profitability, GANX's ROE is -2.48%, compared to RNA's ROE of -0.27%. Regarding short-term risk, GANX is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check RNA's competition here
GANX vs ADMA Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, ADMA has a market cap of 4.4B. Regarding current trading prices, GANX is priced at $1.50, while ADMA trades at $18.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas ADMA's P/E ratio is 22.13. In terms of profitability, GANX's ROE is -2.48%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, GANX is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check ADMA's competition here
GANX vs KRYS Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, KRYS has a market cap of 4.4B. Regarding current trading prices, GANX is priced at $1.50, while KRYS trades at $153.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas KRYS's P/E ratio is 36.74. In terms of profitability, GANX's ROE is -2.48%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, GANX is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check KRYS's competition here
GANX vs CYTK Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, CYTK has a market cap of 4.3B. Regarding current trading prices, GANX is priced at $1.50, while CYTK trades at $36.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas CYTK's P/E ratio is -6.84. In terms of profitability, GANX's ROE is -2.48%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, GANX is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check CYTK's competition here
GANX vs ZLAB Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, ZLAB has a market cap of 4.3B. Regarding current trading prices, GANX is priced at $1.50, while ZLAB trades at $38.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas ZLAB's P/E ratio is -15.43. In terms of profitability, GANX's ROE is -2.48%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, GANX is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check ZLAB's competition here
GANX vs OPT Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, GANX is priced at $1.50, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas OPT's P/E ratio is -1.52. In terms of profitability, GANX's ROE is -2.48%, compared to OPT's ROE of +2.60%. Regarding short-term risk, GANX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check OPT's competition here
GANX vs MRTX Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, GANX is priced at $1.50, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas MRTX's P/E ratio is -4.82. In terms of profitability, GANX's ROE is -2.48%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, GANX is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check MRTX's competition here
GANX vs PTCT Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, PTCT has a market cap of 4B. Regarding current trading prices, GANX is priced at $1.50, while PTCT trades at $50.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas PTCT's P/E ratio is 7.82. In terms of profitability, GANX's ROE is -2.48%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, GANX is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check PTCT's competition here
GANX vs ACLX Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, ACLX has a market cap of 3.9B. Regarding current trading prices, GANX is priced at $1.50, while ACLX trades at $71.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas ACLX's P/E ratio is -23.93. In terms of profitability, GANX's ROE is -2.48%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, GANX is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check ACLX's competition here
GANX vs ACAD Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, ACAD has a market cap of 3.9B. Regarding current trading prices, GANX is priced at $1.50, while ACAD trades at $23.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas ACAD's P/E ratio is 17.18. In terms of profitability, GANX's ROE is -2.48%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, GANX is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check ACAD's competition here
GANX vs AKRO Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, AKRO has a market cap of 3.8B. Regarding current trading prices, GANX is priced at $1.50, while AKRO trades at $47.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas AKRO's P/E ratio is -12.73. In terms of profitability, GANX's ROE is -2.48%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, GANX is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check AKRO's competition here
GANX vs VKTX Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, GANX is priced at $1.50, while VKTX trades at $33.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas VKTX's P/E ratio is -21.89. In terms of profitability, GANX's ROE is -2.48%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, GANX is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check VKTX's competition here
GANX vs RYZB Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, GANX is priced at $1.50, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas RYZB's P/E ratio is -57.86. In terms of profitability, GANX's ROE is -2.48%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, GANX is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check RYZB's competition here
GANX vs CBAY Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, GANX is priced at $1.50, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas CBAY's P/E ratio is -32.81. In terms of profitability, GANX's ROE is -2.48%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, GANX is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check CBAY's competition here
GANX vs LEGN Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, LEGN has a market cap of 3.7B. Regarding current trading prices, GANX is priced at $1.50, while LEGN trades at $40.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas LEGN's P/E ratio is -34.25. In terms of profitability, GANX's ROE is -2.48%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, GANX is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check LEGN's competition here
GANX vs MTSR Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, MTSR has a market cap of 3.7B. Regarding current trading prices, GANX is priced at $1.50, while MTSR trades at $35.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas MTSR's P/E ratio is -13.93. In terms of profitability, GANX's ROE is -2.48%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, GANX is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for GANX.Check MTSR's competition here
GANX vs SRRK Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, SRRK has a market cap of 3.6B. Regarding current trading prices, GANX is priced at $1.50, while SRRK trades at $37.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas SRRK's P/E ratio is -14.82. In terms of profitability, GANX's ROE is -2.48%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, GANX is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check SRRK's competition here
GANX vs SWTX Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, GANX is priced at $1.50, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas SWTX's P/E ratio is -13.78. In terms of profitability, GANX's ROE is -2.48%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, GANX is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check SWTX's competition here
GANX vs AAPG Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, AAPG has a market cap of 3.5B. Regarding current trading prices, GANX is priced at $1.50, while AAPG trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas AAPG's P/E ratio is -50.00. In terms of profitability, GANX's ROE is -2.48%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, GANX is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check AAPG's competition here
GANX vs PTGX Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, PTGX has a market cap of 3.4B. Regarding current trading prices, GANX is priced at $1.50, while PTGX trades at $54.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas PTGX's P/E ratio is 70.03. In terms of profitability, GANX's ROE is -2.48%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, GANX is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check PTGX's competition here
GANX vs MLTX Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, MLTX has a market cap of 3.2B. Regarding current trading prices, GANX is priced at $1.50, while MLTX trades at $50.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas MLTX's P/E ratio is -21.94. In terms of profitability, GANX's ROE is -2.48%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, GANX is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for GANX.Check MLTX's competition here
GANX vs KYMR Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, KYMR has a market cap of 3.1B. Regarding current trading prices, GANX is priced at $1.50, while KYMR trades at $44.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas KYMR's P/E ratio is -14.17. In terms of profitability, GANX's ROE is -2.48%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, GANX is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check KYMR's competition here
GANX vs MORF Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, GANX is priced at $1.50, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas MORF's P/E ratio is -14.88. In terms of profitability, GANX's ROE is -2.48%, compared to MORF's ROE of -0.22%. Regarding short-term risk, GANX is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check MORF's competition here
GANX vs MOR Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, GANX is priced at $1.50, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas MOR's P/E ratio is -12.64. In terms of profitability, GANX's ROE is -2.48%, compared to MOR's ROE of -1.84%. Regarding short-term risk, GANX is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check MOR's competition here
GANX vs IMVT Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, IMVT has a market cap of 2.8B. Regarding current trading prices, GANX is priced at $1.50, while IMVT trades at $16.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas IMVT's P/E ratio is -6.09. In terms of profitability, GANX's ROE is -2.48%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, GANX is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check IMVT's competition here
GANX vs CRNX Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, CRNX has a market cap of 2.7B. Regarding current trading prices, GANX is priced at $1.50, while CRNX trades at $29.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas CRNX's P/E ratio is -7.69. In terms of profitability, GANX's ROE is -2.48%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, GANX is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check CRNX's competition here
GANX vs KDNY Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, GANX is priced at $1.50, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas KDNY's P/E ratio is -12.47. In terms of profitability, GANX's ROE is -2.48%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, GANX is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check KDNY's competition here
GANX vs MYOV Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, GANX is priced at $1.50, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas MYOV's P/E ratio is -14.05. In terms of profitability, GANX's ROE is -2.48%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, GANX is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check MYOV's competition here
GANX vs LGND Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, LGND has a market cap of 2.6B. Regarding current trading prices, GANX is priced at $1.50, while LGND trades at $135.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas LGND's P/E ratio is -18.55. In terms of profitability, GANX's ROE is -2.48%, compared to LGND's ROE of -0.16%. Regarding short-term risk, GANX is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check LGND's competition here
GANX vs CPRX Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, CPRX has a market cap of 2.6B. Regarding current trading prices, GANX is priced at $1.50, while CPRX trades at $21.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas CPRX's P/E ratio is 13.55. In terms of profitability, GANX's ROE is -2.48%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, GANX is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check CPRX's competition here
GANX vs RARE Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, RARE has a market cap of 2.6B. Regarding current trading prices, GANX is priced at $1.50, while RARE trades at $27.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas RARE's P/E ratio is -4.66. In terms of profitability, GANX's ROE is -2.48%, compared to RARE's ROE of -1.86%. Regarding short-term risk, GANX is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check RARE's competition here
GANX vs MIRM Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, MIRM has a market cap of 2.5B. Regarding current trading prices, GANX is priced at $1.50, while MIRM trades at $51.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas MIRM's P/E ratio is -31.75. In terms of profitability, GANX's ROE is -2.48%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, GANX is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check MIRM's competition here
GANX vs NAMS Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, NAMS has a market cap of 2.5B. Regarding current trading prices, GANX is priced at $1.50, while NAMS trades at $22.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas NAMS's P/E ratio is -12.19. In terms of profitability, GANX's ROE is -2.48%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, GANX is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check NAMS's competition here
GANX vs RXRX Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, RXRX has a market cap of 2.5B. Regarding current trading prices, GANX is priced at $1.50, while RXRX trades at $5.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas RXRX's P/E ratio is -3.23. In terms of profitability, GANX's ROE is -2.48%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, GANX is more volatile compared to RXRX. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check RXRX's competition here
GANX vs NAMSW Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, NAMSW has a market cap of 2.4B. Regarding current trading prices, GANX is priced at $1.50, while NAMSW trades at $11.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas NAMSW's P/E ratio is N/A. In terms of profitability, GANX's ROE is -2.48%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, GANX is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check NAMSW's competition here
GANX vs APLS Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, APLS has a market cap of 2.4B. Regarding current trading prices, GANX is priced at $1.50, while APLS trades at $19.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas APLS's P/E ratio is -10.56. In terms of profitability, GANX's ROE is -2.48%, compared to APLS's ROE of -1.00%. Regarding short-term risk, GANX is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check APLS's competition here
GANX vs PRVB Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, GANX is priced at $1.50, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas PRVB's P/E ratio is -16.43. In terms of profitability, GANX's ROE is -2.48%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, GANX is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check PRVB's competition here
GANX vs XENE Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, XENE has a market cap of 2.4B. Regarding current trading prices, GANX is priced at $1.50, while XENE trades at $30.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas XENE's P/E ratio is -9.56. In terms of profitability, GANX's ROE is -2.48%, compared to XENE's ROE of -0.32%. Regarding short-term risk, GANX is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check XENE's competition here
GANX vs LBPH Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, GANX is priced at $1.50, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas LBPH's P/E ratio is -26.66. In terms of profitability, GANX's ROE is -2.48%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, GANX is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check LBPH's competition here
GANX vs DICE Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, GANX is priced at $1.50, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas DICE's P/E ratio is -21.91. In terms of profitability, GANX's ROE is -2.48%, compared to DICE's ROE of +0.56%. Regarding short-term risk, GANX is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check DICE's competition here
GANX vs IBRX Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, IBRX has a market cap of 2.3B. Regarding current trading prices, GANX is priced at $1.50, while IBRX trades at $2.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas IBRX's P/E ratio is -4.49. In terms of profitability, GANX's ROE is -2.48%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, GANX is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check IBRX's competition here
GANX vs APGE Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, APGE has a market cap of 2.2B. Regarding current trading prices, GANX is priced at $1.50, while APGE trades at $37.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas APGE's P/E ratio is -10.42. In terms of profitability, GANX's ROE is -2.48%, compared to APGE's ROE of -0.19%. Regarding short-term risk, GANX is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check APGE's competition here
GANX vs IDYA Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, IDYA has a market cap of 2.2B. Regarding current trading prices, GANX is priced at $1.50, while IDYA trades at $25.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas IDYA's P/E ratio is -6.95. In terms of profitability, GANX's ROE is -2.48%, compared to IDYA's ROE of -0.29%. Regarding short-term risk, GANX is more volatile compared to IDYA. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check IDYA's competition here
GANX vs CNTA Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, CNTA has a market cap of 2.2B. Regarding current trading prices, GANX is priced at $1.50, while CNTA trades at $16.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas CNTA's P/E ratio is -8.81. In terms of profitability, GANX's ROE is -2.48%, compared to CNTA's ROE of -0.57%. Regarding short-term risk, GANX is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for GANX.Check CNTA's competition here
GANX vs KNSA Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, KNSA has a market cap of 2.2B. Regarding current trading prices, GANX is priced at $1.50, while KNSA trades at $30.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas KNSA's P/E ratio is 601.20. In terms of profitability, GANX's ROE is -2.48%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, GANX is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check KNSA's competition here
GANX vs GLPG Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, GLPG has a market cap of 2.2B. Regarding current trading prices, GANX is priced at $1.50, while GLPG trades at $33.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas GLPG's P/E ratio is -6.47. In terms of profitability, GANX's ROE is -2.48%, compared to GLPG's ROE of -0.10%. Regarding short-term risk, GANX is more volatile compared to GLPG. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check GLPG's competition here
GANX vs AGIO Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, AGIO has a market cap of 2.2B. Regarding current trading prices, GANX is priced at $1.50, while AGIO trades at $37.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas AGIO's P/E ratio is 3.25. In terms of profitability, GANX's ROE is -2.48%, compared to AGIO's ROE of +0.50%. Regarding short-term risk, GANX is more volatile compared to AGIO. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check AGIO's competition here
GANX vs ARWR Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, ARWR has a market cap of 2.2B. Regarding current trading prices, GANX is priced at $1.50, while ARWR trades at $15.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas ARWR's P/E ratio is -12.67. In terms of profitability, GANX's ROE is -2.48%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, GANX is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check ARWR's competition here
GANX vs CALT Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, GANX is priced at $1.50, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas CALT's P/E ratio is -22.73. In terms of profitability, GANX's ROE is -2.48%, compared to CALT's ROE of -1.67%. Regarding short-term risk, GANX is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check CALT's competition here
GANX vs BLTE Comparison July 2025
GANX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GANX stands at 51.9M. In comparison, BLTE has a market cap of 2.1B. Regarding current trading prices, GANX is priced at $1.50, while BLTE trades at $64.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GANX currently has a P/E ratio of -1.81, whereas BLTE's P/E ratio is -47.65. In terms of profitability, GANX's ROE is -2.48%, compared to BLTE's ROE of -0.32%. Regarding short-term risk, GANX is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for GANX.Check BLTE's competition here